{"id":"0bb667c9-e4d2-589b-bf8b-fcf0521fa479","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-mouse-cd38-activity","predicate":"decreases_in_recorded_comparison","statement":"Apigenin reduced hepatic CD38 activity in high-fat-fed mice.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"d0ad63f6-9cf7-515c-8265-a360fc70e9f1","mechanism_event_label":"Apigenin reduced hepatic CD38 activity in high-fat-fed mice.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"77c40786-fc17-5efb-887f-52a76163a9ba","slug":"mouse-cd38","display_name":"Mouse CD38","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"d0ad63f6-9cf7-515c-8265-a360fc70e9f1","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-mouse-cd38-activity-event","event_type":"experimental_observation","label":"Apigenin reduced hepatic CD38 activity in high-fat-fed mice.","description":"### api-mouse-cd38-activity\n\nApigenin reduced hepatic CD38 activity in high-fat-fed mice.\nThis pharmacological injection regimen is not a dietary human exposure.\nModel and exposure: 100 mg/kg intraperitoneally daily for 7 days; n=6 per group.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin in high-fat-fed mice","sequence_order":0,"notes":""},{"entity":{"id":"77c40786-fc17-5efb-887f-52a76163a9ba","slug":"mouse-cd38","display_name":"Mouse CD38","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin in high-fat-fed mice\", \"comparator\": \"High-fat-fed vehicle controls\", \"endpoint\": \"Apigenin reduced hepatic CD38 activity in high-fat-fed mice.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"100 mg/kg intraperitoneally daily for 7 days; n=6 per group.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin reduced hepatic CD38 activity in high-fat-fed mice.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-mouse-cd38-activity; This pharmacological injection regimen is not a dietary human exposure.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7cc19d96-dfe2-5838-9703-f4ec08a8d131","evidence_kind":"source_excerpt","locator":"Lines 216-222","start_line":216,"end_line":222,"excerpt":"### api-mouse-cd38-activity\n\nApigenin reduced hepatic CD38 activity in high-fat-fed mice.\nThis pharmacological injection regimen is not a dietary human exposure.\nModel and exposure: 100 mg/kg intraperitoneally daily for 7 days; n=6 per group.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"100 mg/kg intraperitoneally daily for 7 days; n=6 per group.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}